Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

UroGen Pharma Ltd. - Ordinary Shares (NQ:URGN)

37.02 -1.22 (-3.19%)
Streaming Delayed Price Updated: 9:49 AM EDT, Aug 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about UroGen Pharma Ltd. - Ordinary Shares

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
PriceSmart Posts Weak Earnings, Joins Roku And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via Business Wire
News headline image
Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Catapults On 'Unprecedented' Results For Gel-Based Cancer Drug ↗
The company is working on a treatment for non-muscle invasive bladder cancer. 
Via Investor's Business Daily
News headline image
UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs
From UroGen Pharma Ltd.
Via Business Wire
News headline image
New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024
From UroGen Pharma Ltd.
Via Business Wire
News headline image
ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Announces FDA Acceptance of its New Drug Application for UGN-102
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Appoints Chris Degnan as Chief Financial Officer
From UroGen Pharma Ltd.
Via Business Wire
News headline image
First Patient Dosed in Phase 3 Clinical Trial of UGN-103, a Next Generation Mitomycin-Based Formulation in Development for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Receives New U.S. Patent Allowance for Next-Generation Mitomycin-Based Products Expected to Provide Protection Until December 2041
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma to Present at Upcoming Investor Conferences
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Submits Completed UGN-102 NDA Seeking Approval as the First FDA-Approved Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
From UroGen Pharma Ltd.
Via Business Wire
News headline image
URGN Stock Earnings: UroGen Pharma Misses EPS, Misses Revenue for Q2 2024 ↗
URGN stock results show that UroGen Pharma missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
UroGen Pharma Ahead of Schedule to Complete UGN-102 NDA Submission and Reports 2024 Second Quarter Financial Results and Business Highlights
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma Stock Earns 91 RS Rating ↗
UroGen Pharma stock had its Relative Strength (RS) Rating upgraded to 91 Thursday, up from 87 a day earlier. 
Via Investor's Business Daily
News headline image
NextEra Energy, Lennar And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
From UroGen Pharma Ltd.
Via Business Wire
News headline image
Hasbro, Tutor Perini, Arm Holdings And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Hasbro To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Friday ↗
 
Via Benzinga
News headline image
UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma to Host UGN-102 Virtual Data Event on June 13, 2024
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
From UroGen Pharma Ltd.
Via Business Wire
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.